JENNIFER KAUFMAN: Open Payments
NPI 1750405767 · CLARKSTON, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$649 in 34 payments from 10 companies in 2025. Trend: 2023 $562 · 2024 $892 · 2025 $649
Food & beverage: $565Education: $84
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 20 | $285 |
| Janssen Biotech, Inc. | 2 | $112 |
| Ipsen Biopharmaceuticals, Inc | 3 | $51 |
| Gilead Sciences, Inc. | 2 | $48 |
| PFIZER INC. | 2 | $45 |
| Regeneron Healthcare Solutions, Inc. | 1 | $28 |
| Madrigal Pharmaceuticals | 1 | $27 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $18 |
| GENZYME CORPORATION | 1 | $15 |
Products named: MAVYRET, TREMFYA, RINVOQ, IQIRVO, DUPIXENT, CREON, SKYRIZI, REZDIFFRA.
Industry payments across WA — which companies pay providers there.
